Business Context and Reporting Period
Company: BIO-RAD LABORATORIES, INC.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended June 30, 2004
Business Overview: Bio-Rad is a multinational manufacturer and distributor of Life Science research and Clinical Diagnostics products. The company operates two primary segments: Life Science and Clinical Diagnostics. Approximately 70% of revenues are recurring, with 64% of sales generated internationally.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended June 30, 2004 |
3 Months Ended June 30, 2003 |
6 Months Ended June 30, 2004 |
6 Months Ended June 30, 2003 |
|---|---|---|---|---|
| Net Sales | $260,546 | $239,325 | $523,295 | $479,723 |
| Gross Profit | $149,661 | $135,060 | $298,925 | $275,738 |
| Gross Margin % | 57.4% | 56.4% | 57.1% | 57.5% |
| Net Income | $22,863 | $20,956 | $44,841 | $47,320 |
| Diluted EPS | $0.86 | $0.80 | $1.69 | $1.81 |
| Cash from Operations (6mo) | $47,544 | $46,592 | ||
| Cash & Equivalents (End of Period) | ||||
| Total Debt (Current + Long-term) | $236,085 (as of June 30, 2004) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8.9% for the quarter and 9.1% for the six-month period compared to the prior year. Currency fluctuations (weakening US dollar) contributed $11.2 million to quarterly sales and $33.3 million to six-month sales. On a currency-neutral basis, sales grew 4.2% for the quarter and 2.1% for the six months.
- Segment Performance: Clinical Diagnostics sales grew 13.4% (quarter) and 11.8% (six months), driven by quality control, autoimmune, and diabetes products. Life Science sales grew 3.4% (quarter) and 6.1% (six months), though currency-neutral growth was flat or slightly negative due to competitive pricing in the BSE testing market.
- Profitability: Net income increased 9.1% for the quarter but decreased 5.2% for the six months. The six-month decline is largely due to a $2.4 million write-down of an investment in Instrumentation Laboratory, S.p.A., and increased R&D expenses.
- Discontinued Operations: The company sold its confocal microscopy product line to Carl Zeiss Jena GMBH in May 2004, resulting in a net gain of $3.4 million (after tax) recorded in discontinued operations.
- Expenses: SG&A expenses increased as a percentage of sales (34.6% vs 32.2% for the quarter) due to higher spending on advertising, IT, and legal services. R&D expenses increased 16.1% for the quarter.
Guidance, Outlook, and Risks
- Acquisitions: In June 2004, the company signed a letter of intent to acquire MJ GeneWorks, Inc. for approximately $47 million. The transaction is subject to a definitive agreement and has not been completed. The company also acquired the controls business of Hematronix in March 2004.
- Market Outlook: Management notes that the diagnostic market is growing around 3% (currency neutral), while the life science market is growing about 5%. However, government-sponsored research spending has slowed in the US and Japan, and BSE testing faces pricing pressures.
- Debt and Liquidity: The company refinanced its debt in late 2003, issuing $225 million in Senior Subordinated Notes due 2013 at 7.5%. As of June 30, 2004, the company had $155.3 million in cash and $145.5 million available under its revolving credit facility.
- Risks: Key risks include reliance on intellectual property, competition in the BSE testing market, foreign currency fluctuations, and the ability to successfully develop and market new products. The company also faces potential legal liabilities, though none are currently expected to be material.
Investor Verification Checklist
- Acquisition Status: Verify the completion status and final terms of the proposed MJ GeneWorks acquisition.
- Currency Impact: Assess the sensitivity of future earnings to US dollar strength, given 64% of sales are international.
- BSE Market Dynamics: Monitor pricing trends and contract renewals in the competitive Bovine Spongiform Encephalopathy (BSE) testing market.
- Debt Servicing: Review the impact of the increased debt load ($236 million total) on future interest expenses and cash flow.
- R&D Efficiency: Evaluate the return on the 16% increase in R&D spending, particularly regarding the Bioplex 2200 platform and proteomics initiatives.